Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-10-24
2006-10-24
Falk, Anne-Marie (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07125856
ABSTRACT:
A method for treating peripheral neuropathy, particularly ischemic peripheral neuropathy, is provided. The method involves administering to subjects in need of such treatment an effective amount of an angiogenic growth factor to alleviate a symptom of the neuropathy.
REFERENCES:
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5420112 (1995-05-01), Lewis et al.
patent: 5604202 (1997-02-01), Kessler et al.
patent: 5607918 (1997-03-01), Eriksson et al.
patent: 5935820 (1999-08-01), Hu et al.
patent: 6013780 (2000-01-01), Neufeld et al.
patent: WO 92 11360 (1992-07-01), None
patent: WO 97/19693 (1997-06-01), None
patent: WO 99/36103 (1999-07-01), None
Apfel, SC (2001) Neurotrophic factor therapy: Prospects and problems. Clinical Chemistry and Laboratory Medicine 39(4): 351-355.
Baumgartner et al. (1998) Constitutive expression of phVEGF-165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97: 1114-1123.
Friedmann, T. (Jun. 1997) Overcoming the obstacles to gene therapy. Scientific American, Jun. 1997, pp. 96-101.
Isner et al. (1996) Clinical evidence of angiogenesis after arterial gene transfer of phVEGF-165 in patient with ischaemic limb. Lancet 348: 370-374.
Orkin and Motulsky (1995) Report and recommendations of the panel to assess the NIH investment in research on gene therapy. pp. 1-40.
Verma et al. (1997) Gene therapy—promises, problems, and prospects. Nature 389: 239-242.
NINDS Peripheral Neuropathy Information Page (2001), pp. 1-3.
Samii, Amir et al., “Vascular Endothelial Growth Factor Expression in Peripheral Nerves and Dorsal Root Ganglia in Diabetic Neuropathy in Rats,”Neuroscience Letter, 262: 159-162 (1999).
Créange, Alain et al., “Cytokines and Peripheral Nerve Disorder,”Eur. Cytokine Netw., 8, 2: 145-151 (Jun. 1997).
Schratzberger, Peter et al., “Favorable Impact of Therapeutic Angiogenesis on Peripheral Ischemic Neuropathy,”, Abstract. (Feb. 11, 1999).
Duh, Elia, “Vascular Endothelial Growth Factors and Diabetes: The Agonist Versus Antagonist Paradox,”Diabetes, 48: 1899-1906 (Oct. 1999).
Lair JM et al, “Acidic fibroblast growth factor stimulates motor and sensory axon regeneration after sciatic nerve crush in the rat,”Neuroscience, vol. 65, No. 1, 1995, pp. 209-216.
Schratzberger P et al., Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy.Nat Med6(4):405-413 (Apr. 2000).
Schratzberger P et al., Reversal of experimental diabetic neuropathy by VEGF gene transfer.J Clin Invest107(9):1083-1092 (May 2001).
Sondell M et al., Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system.J Neurosci19(14):5731-5740 (Jul. 15, 1999).
Yang, Xiu-Ming et al., “Autocrine Hepatocyte Growth Factor Provides a Local Mechanism for Promoting Axonal Growth,”The Journal of Neuroscience, Oct. 15, 1998, 18(20), pp. 8369-8381.
Falk Anne-Marie
St. Elizabeth's Medical Center of Boston, Inc.
Wolf Greenfield & Sacks P.C.
LandOfFree
Angiogenic growth factors for treatment of peripheral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Angiogenic growth factors for treatment of peripheral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Angiogenic growth factors for treatment of peripheral... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3642373